Reviva Pharma Trades Up As Maxim Initiates With Buy, Target $10

 

• Reviva Pharmaceuticals Holdings Inc RVPH 7.57% is trading higher with around 60k in session volume.
• Maxim initiated coverage of Reviva with a Buy rating and $10 price target, equivalent to an upside of around 140%.
• The company is developing its lead asset, RP5063 (brilaroxazine), to treat schizophrenia and respiratory indications. 
• Analyst Jason McCarthy tells in a research note that RP5063 features a multimodal mechanism of action, which is "more completely" addressing the mix of positive, negative, and cognitive symptoms associated with schizophrenia.
• In April, RP5063 showed positive action in the schizophrenia trial that met its primary endpoint of disease severity versus placebo.

https://www.benzinga.com/general/biotech/21/07/22153536/reviva-pharma-stock-is-trading-higher-after-maxim-initiated-with-buy-target-price-of-10